BellaSeno Expands its Breast Scaffold Trial Following Positive Results
3D Printing Industry
AI SUMMARY
German medical startup BellaSeno has expanded clinical trials for a biodegradable polycaprolactone breast scaffold that regenerates tissue without leaving permanent implants. The company enrolled 30 patients across Australian trials, building on positive safety data from a first-in-human study that ran from 2021 to 2023.
FROM THE ARTICLE
German medical startup BellaSeno has enrolled 30 patients across two Australian trials of a polycaprolactone breast scaffold designed to regenerate tissue without leaving a permanent foreign body. The 30 patients are spread across a first-in-human safety study that ran from 2021 to 2023 and…
This story was originally published by 3D Printing Industry.
Read Full Story on 3D Printing IndustryRelated Stories
Materials & SustainabilityDurable Rooftop DecksJLC OnlineMaterials & SustainabilityRollon launches two telescopic rails with integrated magnetsRobotics Business Review3D Printing & PrefabNSF Backs Automated 3D Printing of Lab-on-a-Chip Devices3D Printing Industry3D Printing & PrefabFIU’s 3D Printed Tiles Reimagine Coastal Protection3D Printing Industry